These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22623764)

  • 1. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.
    Doria-Rose NA; Georgiev I; O'Dell S; Chuang GY; Staupe RP; McLellan JS; Gorman J; Pancera M; Bonsignori M; Haynes BF; Burton DR; Koff WC; Kwong PD; Mascola JR
    J Virol; 2012 Aug; 86(15):8319-23. PubMed ID: 22623764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
    McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
    Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
    Morales JF; Morin TJ; Yu B; Tatsuno GP; O'Rourke SM; Theolis R; Mesa KA; Berman PW
    J Biol Chem; 2014 Jul; 289(30):20526-42. PubMed ID: 24872420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
    Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
    Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant.
    Totrov M
    PLoS One; 2014; 9(4):e94002. PubMed ID: 24705879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
    O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
    PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
    Sullivan N; Thali M; Furman C; Ho DD; Sodroski J
    J Virol; 1993 Jun; 67(6):3674-9. PubMed ID: 8497077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
    Qi Y; Jo S; Im W
    Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
    Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
    Doores KJ; Burton DR
    J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
    Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.
    Pancera M; Yang Y; Louder MK; Gorman J; Lu G; McLellan JS; Stuckey J; Zhu J; Burton DR; Koff WC; Mascola JR; Kwong PD
    PLoS One; 2013; 8(2):e55701. PubMed ID: 23431362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
    Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
    Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.